EMA Clinical Trials Information System (CTIS) Information Day

17 October 2023
13:30 - 17:30 CET | VIRTUAL Event

| PROGRAMME COMMITTEE

Peter Arlett
Head Data Analytics & Methods Task Force
European Medicines Agency, EU

Marianne Lunzer
CTCG Chair
Assessor, Dept of Clinical Trials
AGES, AT

Noémie Manent
Principal Scientific Administrator
European Medicines Agency, EU

| FACULTY

Monique Al
CTCG Vice Chair
Head of the National Clinical Trial Office
Central Committee on Research
Involving Human Subjects (CCMO), NL

Caroline Correas
Associate Director, Global Regulatory
Policy, Global Regulatory Science
Bristol Myers Squibb, CH

Christophe Didion
European Commission, BE

Elena García Méndez
Member of the Technical Secretariat of
the Ethics Committee
Hospital Universitario La Paz, ES

Scott Feiner
Clinical Records Management
Strategic Clinical Operations
AbbVie, US

Laura Lavin de Juan
Head of Service in the Clinical Trials
Division
Spanish Agency for Medicines and
Medical Devices, AEMPS, ES

Roxana Spulber
Change Management Officer
European Medicines Agency, EU

Leonard Van den Berg
University Medical Center (UMC)
Utrecht, NL

| OVERVIEW

The Clinical Trials Information System (CTIS) is the backbone of the Clinical Trials Regulation (Regulation (EU) No 536/2014) and acts as a the single-entry point for clinical trials assessment, authorisation and supervision in the EEA.

It also enables the publication and registration of clinical trials in the CTIS public website that is a public register with search and download functionalities.

CTIS provides harmonised and simplified end-to-end electronic application procedures over the lifecycle of clinical trials across the EU/EEA.

Since the launch of CTIS on 31 January 2023, only 15 months remain to transition ongoing trials from the previous legislative framework of the Clinical Trials Directive (2001/20/EC) to the Clinical Trial Regulation (536/2014).

The virtual event aims to support sponsors of clinical trials in preparing and proceeding with the transition to meet the deadline of 30 January 2025. Commercial and non-commercial sponsors with experience in transitioning trials as well as representatives from EMA and EU/EEA member states will share insights and best practices.

Ample time is foreseen for Q&A. The faculty invites participants to submit related questions by 03 October 2023 latest to emaevents@diaglobal.org

| KEY TOPICS

- Transition period from the Clinical Trials Directive (2001/20/EC) to the Clinical Trial Regulation – regulatory and practical aspects
- Insights on preparation for transitioning clinical trials from sponsors' perspective.
- Insights on member states procedures with regard to transitioning of clinical trials.
- CTIS system metrics
- Upcoming training and event opportunities

| TARGET AUDIENCE

This EMA CTIS Virtual Information Day is aimed at CTIS users from:

- Pharmaceutical companies
- Small and medium sized enterprises (SMEs)
- Academic organisations
- Contract Research Organisations (CROs)
- Member State NCAs
- Ethics Committee Members

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

DIA

AGENDA | 17 OCTOBER 2023 | 13:30 – 17:30 CET

13:30	**WELCOME NOTE** Peter Arlett, EMA, EU
	SESSION CHAIRS : Marianne Lunzer, AGES, AT & Noémie Manent, EMA, EU
	TRANSITION PERIODS FOR CLINICAL TRIALS FROM DIRECTIVE (2001/20/EC) TO REGULATION (536/2014)
13:50	**Transitioning Clinical Trials - Regulatory Considerations** Christophe Didion, European Commission
14:10	**Transitioning Clinical Trials – Considerations From Sponsor Perspective** Caroline Correas, Bristol Myers Squibb, CH
14:30	**Member States And Ethics Committee Experience And Insights Related To Transitioning Clinical Trials** Elena García Méndez, Member of the Technical Secretariat of the Ethics Committee , Hospital Universitario La Paz, ES & Laura Lavin de Juan, AEMPS, ES
15:00	**Member States Best Practice Guidance For Sponsors To Transition Clinical Trials** Monique Al, CTCG Vice-Chair, CCMO, NL
15:20	Q&A and panel discussion
15:45	BREAK
16:15	**Practical Insights Of Transitioning Clinical Trials From Industry Sponsor Perspective** Scott Feiner, AbbVie
16:35	**Practical Insights Of Transitioning Clinical Trials From Academia Sponsor Perspective** Leonard van den Berg, UMC Utrecht, NL
16:55	Q&A and panel discussion
17:25	**WRAP UP and Closing** Noémie Manent, European Medicines Agency, EU
17:30	**END OF THE INFORMATION DAY**